Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide

Bardania, Hassan; Shojaosadati, Seyed Abbas; Kobarfard, Farzad; Dorkoosh, Farid Abedin

doi:10.15171/ijb.1399

Cited by 23 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46.17% ex vivo antiplatelet activity for eptifibatide encapsulated into RGD modified nanoliposomes compared with free drug)Bardania, Shojaosadati, Kobarfard, & Dorkoosh, 2016). They demonstrated that targeted liposomes containing streptokinase can accelerate the clot lysis and improve the efficacy of streptokinase activity to lyse clots (Vaidya, Nayak, Dash, Agrawal, & Vyas, 2011).…”

mentioning

confidence: 99%

“…In another study by Bardania et al, eptifibatide (as antiplatelet agents) was encapsulated into RGD-modified nanoliposomes and its efficacy investigated by in vivo and ex vivo aggregometer analysis. They revealed that eptifibatide encapsulated into nanoliposomes targeted with RGD peptide had more significant antiplatelet activity compared with free and eptifibatide encapsulated unmodified liposome (81.63 vs. 46.17% ex vivo antiplatelet activity for eptifibatide encapsulated into RGD modified nanoliposomes compared with free drug)Bardania, Shojaosadati, Kobarfard, & Dorkoosh, 2016).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Recent progress in biomedical applications of RGD‐based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review

Alipour

Baneshi

Hosseinkhani

et al. 2019

J Biomedical Materials Res

Self Cite

107

View full text Add to dashboard Cite

Arginine-glycine-aspartic acid (RGD) peptide family is known as the most prominent ligand for extracellular domain of integrin receptors. Specific expression of these receptors in various tissue of human body and tight association of their expression profile with various pathophysiological conditions made these receptors a suitable targeting candidate for several disease diagnosis and treatment as well as regeneration of various organs. For these reasons, various forms of RGD-based integrins ligands have been greatly used in biomedical studies. Here, we summarized the last decade application progress of RGD for cancer theranostics, control of inflammation, thrombosis inhibition and critically discussed the effect of RGD peptides structure and sequence on the efficacy of gene/drug delivery systems in preclinical studies. Furthermore, we will show recent advances in application of RGD functionalized biomaterials for various tissue regenerations including cornea repair, artificial neovascularization and bone tissue regeneration.Finally, we analyzed clinically translatability of RGD peptides, considering examples of integrin ligands in clinical trials. In conclusion, prospects on using RGD peptide for precise drug delivery and biomaterial engineering are well discussed.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Recent progress in biomedical applications of RGD‐based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review

Alipour

Baneshi

Hosseinkhani

et al. 2019

J Biomedical Materials Res

Self Cite

107

View full text Add to dashboard Cite

show abstract

“…Models of EE and liposome size were constructed, which allow the evaluation of the significance of the parameters and provide the prediction capability for EE and size. The utilization of RSM is a powerful methodology in the enhancement of the optimization of the liposomal preparation within a designed experiment [ 29 , 30 , 31 , 32 ]. Based on the statistical theory with 2 5−1 fractional factorial design, a central composite rotatable design (CCRD) was adopted to design the experiments using four variables and five levels ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

Optimization of the Preparation of Magnetic Liposomes for the Combined Use of Magnetic Hyperthermia and Photothermia in Dual Magneto-Photothermal Cancer Therapy

Anilkumar

Chen

2020

IJMS

View full text Add to dashboard Cite

In this work, we aimed to develop liposomal nanocomposites containing citric-acid-coated iron oxide magnetic nanoparticles (CMNPs) for dual magneto-photothermal cancer therapy induced by alternating magnetic field (AMF) and near-infrared (NIR) lasers. Toward this end, CMNPs were encapsulated in cationic liposomes to form nano-sized magnetic liposomes (MLs) for simultaneous magnetic hyperthermia (MH) in the presence of AMF and photothermia (PT) induced by NIR laser exposure, which amplified the heating efficiency for dual-mode cancer cell killing and tumor therapy. Since the heating capability is directly related to the amount of entrapped CMNPs in MLs, while the liposome size is important to allow internalization by cancer cells, response surface methodology was utilized to optimize the preparation of MLs by simultaneously maximizing the encapsulation efficiency (EE) of CMNPs in MLs and minimizing the size of MLs. The experimental design was performed based on the central composite rotatable design. The accuracy of the model was verified from the validation experiments, providing a simple and effective method for fabricating the best MLs, with an EE of 87% and liposome size of 121 nm. The CMNPs and the optimized MLs were fully characterized from chemical and physical perspectives. In the presence of dual AMF and NIR laser treatment, a suspension of MLs demonstrated amplified heat generation from dual hyperthermia (MH)–photothermia (PT) in comparison with single MH or PT. In vitro cell culture experiments confirmed the efficient cellular uptake of the MLs from confocal laser scanning microscopy due to passive accumulation in human glioblastoma U87 cells originated from the cationic nature of MLs. The inducible thermal effects mediated by MLs after endocytosis also led to enhanced cytotoxicity and cumulative cell death of cancer cells in the presence of AMF–NIR lasers. This functional nanocomposite will be a potential candidate for bimodal MH–PT dual magneto-photothermal cancer therapy.

show abstract

“…On the one hand, when an external magnetic field was applied, magnetic Fe 3 O 4 /mesoporous silica composite particles with NK can be delivered to the targeted area (Zhang et al, ). On the other hand, arginine‐glycine‐aspartic peptide (RGD) connected to the periphery of nanoparticles can specifically reduce the binding of fibrinogen and receptor GP IIb/IIIa, thereby inhibit the deterioration of platelet aggregation in thrombus, and improve the utilization of thrombolytic drug (Bardania, Shojaosadati, Kobarfard, & Dorkoosh, ; Hagisawa et al, ).…”

Section: Introductionmentioning

confidence: 99%

Synthesis of mesoporous silica/polyglutamic acid peptide dendrimer with dual targeting and its application in dissolving thrombus

Huang

Zhang

Lü

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

With the frequent occurrence of thrombus diseases, thrombus has become a factor endangering human health. Nattokinase (NK) is a new generation of thrombolytic drug with efficient thrombolytic effect and no major side effects. However, it is easily inactivated in external environment due to its sensitivity, which is still a challenge for its generalized application. Herein, a mesoporous silica/polyglutamic acid peptide dendrimer (M‐MSNs‐G3‐RGD) nanoparticle was prepared to protect and transport NK. First, magnetic mesoporous silica nanoparticles (M‐MSNs) were prepared as the core of the whole nanoparticle, then polyglutamic acid peptide dendrimer (G3) was bonded to form M‐MSNs‐G3. At last, arginine‐glycine‐aspartic peptide (RGD) was grafted onto the M‐MSNs‐G3 to obtain M‐MSNs‐G3‐RGD. The physical and chemical characteristics and biological toxicity of M‐MSNs‐G3‐RGD were studied. Thrombus‐targeting nanocomposites M‐MSNs‐G3‐RGD/NK were prepared by loading the thrombolytic drug NK via electrostatic interaction. In vitro and in vivo targeted thrombolytic experiments showed that the nanoparticles exhibited significant thrombolysis ability. These results suggested the potential application of M‐MSNs‐G3‐RGD/NK in dual targeted thrombolysis.

show abstract

Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide

Cited by 23 publications

References 31 publications

Recent progress in biomedical applications of RGD‐based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review

Recent progress in biomedical applications of RGD‐based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review

Optimization of the Preparation of Magnetic Liposomes for the Combined Use of Magnetic Hyperthermia and Photothermia in Dual Magneto-Photothermal Cancer Therapy

Synthesis of mesoporous silica/polyglutamic acid peptide dendrimer with dual targeting and its application in dissolving thrombus

Contact Info

Product

Resources

About